Microbiota issue in CKD: how promising are gut-targeted approaches?
- 258 Downloads
In chronic kidney disease (CKD), the progressive decline in the renal excretory function leads to accumulation of urea and toxins in the blood. The CKD-associated dysbiosis of gut microbiota further contributes to uremia by increasing intestinal toxins production. Gut microbiota is involved in a complex network of human organs, mediated by microbial metabolites: in CKD, gut–heart and gut–brain axes may have a role in increased cardiovascular risk and neuropsychiatric disorders. While the cardiovascular toxicity of some microbial molecules is well known, their presumptive neurotoxicity needs to be confirmed by specific studies. In this review, we describe gut–heart and gut–brain axes in CKD, with an overview of the experimental and human studies characterizing CKD-associated gut microbiota, and we discuss the benefits coming from new approaches aimed at gut manipulation. Microbiota metabolism is emerging as a modifiable non-traditional risk factor in nephrology. In order to take advantage of this issue, it is necessary to consider the microbiota manipulation as part of the nutritional management of CKD. Integrating the low-protein nutritional approach with prebiotic, probiotic and synbiotic supplementation is a promising tool to control disease progression and comorbidities, though an extensive validation in large-scale clinical trials is still required.
KeywordsCKD Gut microbiota Uremic toxins Cardiovascular disease Gut–brain axis Nutrition
This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
For this type of study formal consent is not required.
- 3.Wong J, Piceno YM, DeSantis TZ, Pahl M, Andersen GL, Vaziri ND (2014) Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 39(3):230–237. https://doi.org/10.1159/000360010 Google Scholar
- 6.Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T (2012) Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403(7):1841–1850. https://doi.org/10.1007/s00216-012-5929-3 Google Scholar
- 9.Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL (2015) Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116(3):448–455. https://doi.org/10.1161/CIRCRESAHA.116.305360 Google Scholar
- 13.D’Apolito M, Du X, Zong H, Catucci A, Maiuri L, Trivisano T, Pettoello-Mantovani M, Campanozzi A, Raia V, Pessin JE, Brownlee M, Giardino I (2010) Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Investig 120(1):203–213. https://doi.org/10.1172/JCI37672 Google Scholar
- 15.Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y (1996) Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349–355. https://doi.org/10.1159/000189334 Google Scholar
- 16.Jiang S, Xie S, Lv D, Zhang Y, Deng J, Zeng L, Chen Y (2016) A reduction in the butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is associated with chronic kidney disease progression. Antonie Van Leeuwenhoek 109(10):1389–1396. https://doi.org/10.1007/s10482-016-0737-y Google Scholar
- 18.De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M, Gesualdo L (2014) Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One 9(6):e99006. https://doi.org/10.1371/journal.pone.0099006 Google Scholar
- 22.Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, Kulkarni OP, Mulay SR, Romoli S, Demleitner J, Schiller P, Dietrich A, Müller S, Gross O, Ruscheweyh HJ, Huson DH, Stecher B, Anders HJ (2017) Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J Am Soc Nephrol 28(1):76–83. https://doi.org/10.1681/ASN.2015111285 Google Scholar
- 23.Viggiano D, Ianiro G, Vanella G, Bibbò S, Bruno G, Simeone G, Mele G (2015) Gut barrier in health and disease: focus on childhood. Eur Rev Med Pharmacol Sci 19(6):1077–1085Google Scholar
- 24.Mishima E, Fukuda S, Shima H, Hirayama A, Akiyama Y, Takeuchi Y, Fukuda NN, Suzuki T, Suzuki C, Yuri A, Kikuchi K, Tomioka Y, Ito S, Soga T, Abe T (2015) Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 26(8):1787–1794. https://doi.org/10.1681/ASN.2014060530 Google Scholar
- 27.Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM (2017) Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology 66(6):1727–1738. https://doi.org/10.1002/hep.29306 Google Scholar
- 28.Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimbürger O, Lindholm B, Bergström J (2002) Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13(Suppl 1):S28–S36Google Scholar
- 33.Shafi T, Sirich TL, Meyer TW, Hostetter TH, Plummer NS, Hwang S, Melamed ML, Banerjee T, Coresh J, Powe NR (2017) Results of the HEMO study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney Int 92(6):1484–1492. https://doi.org/10.1016/j.kint.2017.05.012 Google Scholar
- 36.Lopes AA, Bragg J, Young E, Goodkin D, Mapes D, Combe C, Piera L, Held P, Gillespie B, Port FK, Dialysis Outcomes and Practice Patterns Study (DOPPS) (2002) Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 62(1):199–207. https://doi.org/10.1046/j.1523-1755.2002.00411.x Google Scholar
- 39.Karu N, Mckercher C, Nichols DS, Davies N, Shellie RA, Hilder EF, Jose MD (2016) Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian chronic kidney disease pilot study. BMC Nephrol 17(1):171. https://doi.org/10.1186/s12882-016-0387-3 Google Scholar
- 41.Hsu HJ, Yen CH, Chen CK, Wu IW, Lee CC, Sun CY, Chang SJ, Chou CC, Hsieh MF, Chen CY, Hsu CY, Tsai CJ, Wu MS (2013) Association between uremic toxins and depression in patients with chronic kidney disease undergoing maintenance hemodialysis. Gen Hosp Psychiatry 35(1):23–27. https://doi.org/10.1016/j.genhosppsych.2012.08.009 Google Scholar
- 42.Yeh YC, Huang MF, Liang SS, Hwang SJ, Tsai JC, Liu TL, Wu PH, Yang YH, Kuo KC, Kuo MC, Chen CS (2016) Indoxyl sulfate, not p-cresyl sulfate, is associated with cognitive impairment in early-stage chronic kidney disease. Neurotoxicology 53:148–152. https://doi.org/10.1016/j.neuro.2016.01.006 Google Scholar
- 43.Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83(1):57–66Google Scholar
- 45.Oshima N, Onimaru H, Matsubara H, Uchida T, Watanabe A, Takechi H, Nishida Y, Kumagai H (2015) Uric acid, indoxyl sulfate, and methylguanidine activate bulbospinal neurons in the RVLM via their specific transporters and by producing oxidative stress. Neuroscience 304:133–145. https://doi.org/10.1016/j.neuroscience.2015.07.055 Google Scholar
- 47.Piccoli GB, Capizzi I, Vigotti FN, Leone F, D’Alessandro C, Giuffrida D, Nazha M, Roggero S, Colombi N, Mauro G, Castelluccia N, Cupisti A, Avagnina P (2016) Low protein diets in patients with chronic kidney disease: a bridge between mainstream and complementary-alternative medicines? BMC Nephrol 17(1):76. https://doi.org/10.1186/s12882-016-0275-x Google Scholar
- 48.Brenner BM, Meyer TW, Hostetter TH (1982) Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307(11):652–659. https://doi.org/10.1056/NEJM198209093071104 Google Scholar
- 50.Bellizzi V, Di Iorio BR, De Nicola L, Minutolo R, Zamboli P, Trucillo P, Catapano F, Cristofano C, Scalfi L, Conte G, ERIKA Study-Group (2007) Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease. Kidney Int 71(3):245–251. https://doi.org/10.1038/sj.ki.5001955 Google Scholar
- 51.Cianciaruso B, Pota A, Pisani A, Torraca S, Annecchini R, Lombardi P, Capuano A, Nazzaro P, Bellizzi V, Sabbatini M (2008) Metabolic effects of two low protein diets in chronic kidney disease stage 4–5 a randomized controlled trial. Nephrol Dial Transplant 23(2):636–644. https://doi.org/10.1093/ndt/gfm576 Google Scholar
- 53.Brunori G, Viola BF, Parrinello G, De Biase V, Como G, Franco V, Garibotto G, Zubani R, Cancarini GC (2007) Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis 49(5):569–580. https://doi.org/10.1053/j.ajkd.2007.02.278 Google Scholar
- 54.Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, Tam P, Rao AV, Anteyi E, Musso CG (2010) Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 27(9):634–647. https://doi.org/10.1007/s12325-010-0059-9 Google Scholar
- 56.Bliss DZ, Stein TP, Schleifer CR, Settle RG (1996) Supplementation with gum arabic fiber increases fecal nitrogen excretion and lowers serum urea nitrogen concentration in chronic renal failure patients consuming a low-protein diet. Am J Clin Nutr 63:392–398Google Scholar
- 58.Rossi M, Johnson DW, Xu H, Carrero JJ, Pascoe E, French C, Campbell KL (2015) Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Nutr Metab Cardiovasc Dis 25(9):860–865. https://doi.org/10.1016/j.numecd.2015.03.015 Google Scholar
- 59.Cosola C, De Angelis M, Rocchetti MT, Montemurno E, Maranzano V, Dalfino G, Manno C, Zito A, Gesualdo M, Ciccone MM, Gobbetti M, Gesualdo L (2017) Beta-glucans supplementation associates with reduction in p-cresyl sulfate levels and improved endothelial vascular reactivity in healthy individuals. PLoS One 12(1):e0169635. https://doi.org/10.1371/journal.pone.0169635 Google Scholar
- 62.Taki K, Takayama F, Niwa T (2005) Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr 15:77–80Google Scholar
- 63.Ogawa T, Shimada M, Nagano N, Ito K, Ando T, Shimomura Y, Ando Y, Otsuka K (2012) Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Clin Kidney J 5:373–374. https://doi.org/10.1093/ckj/sfs072 Google Scholar
- 64.Wang IK, Wu YY, Yang YF, Ting IW, Lin CC, Yen TH, Chen JH, Wang CH, Huang CC, Lin HC (2015) The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial. Benef Microbes 6(4):423–430. https://doi.org/10.3920/BM2014.0088 Google Scholar
- 65.Soleimani A, Zarrati Mojarrad M, Bahmani F, Taghizadeh M, Ramezani M, Tajabadi-Ebrahimi M, Jafari P, Esmaillzadeh A, Asemi Z (2017) Probiotic supplementation in diabetic hemodialysis patients has beneficial metabolic effects. Kidney Int 91(2):435–442. https://doi.org/10.1016/j.kint.2016.09.040 Google Scholar
- 69.Black AP, Anjos JS, Cardozo L, Carmo FL, Dolenga CJ, Nakao LS, de Carvalho Ferreira D, Rosado A, Carraro Eduardo JC, Mafra D (2018) Does low-protein diet influence the uremic toxin serum levels from the gut microbiota in nondialysis chronic kidney disease patients? J Ren Nutr. https://doi.org/10.1053/j.jrn.2017.11.007 Google Scholar
- 70.Cupisti A, Brunori G, Di Iorio BR, D’Alessandro C, Pasticci F, Cosola C, Bellizzi V, Bolasco P, Capitanini A, Fantuzzi AL, Gennari A, Piccoli GB, Quintaliani G, Salomone M, Sandrini M, Santoro D, Babini P, Fiaccadori E, Gambaro G, Garibotto G, Gregorini M, Mandreoli M, Minutolo R, Cancarini G, Conte G, Locatelli F, Gesualdo L (2018) Nutritional treatment of advanced CKD: twenty consensus statements. J Nephrol. https://doi.org/10.1007/s40620-018-0497-z Google Scholar